Modern biopharma BD: How to find the diamonds in the rough
Learn how top biopharma BD teams find diamonds in the rough by prioritizing strategic clarity, disciplined pipeline triage, and AI-powered asset tracking.
Biopharma
Navigating pharma strategy and portfolio prioritization: A Q&A
With capital markets in flux, regulatory headwinds, and scientific risks, boards and executives must navigate pharma strategy and portfolio prioritization.
Biopharma BD&L: the tsunami is upon us
Pharma’s business development and licensing (BD&L) teams are at the forefront of identifying new science to support their company’s future.
The Great Disruption: how Chinese assets will reshape drug development
Chinese biopharma companies are at an inflection point, with rapid advances in science, know-how, and talent; these assets will reshape drug development.
AI for biopharma business development: finding the right assets faster
By combining human expertise with AI-powered analysis, we’re helping biopharma companies make faster, more informed business development decisions.
3 key ways AI-powered analysis supports drug development
Artificial intelligence-powered pipeline analysis is emerging as a tool that can help teams make better, faster drug development decisions.
5 guardrails you MUST implement when using AI in biopharma
Implementing guardrails for artificial intelligence (AI) in biopharma is crucial for ensuring effective, safe, and compliant use of this powerful technology.